Table 1 General characters of these 31 hepatoblastoma patients
From: Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma
Study population (n = 31) | |
|---|---|
Diagnostic age, medium (IQR), years | 1.0 (0.75–2.00) |
Male gender, n (%) | 19 (61.29%) |
Histology, n (%) | |
Epithelial type | 23 (74.19%) |
Fetal pattern | 14 (45.16%) |
Embryonal pattern | 6 (19.35%) |
Mixed fetal and embryonal pattern | 3 (9.68%) |
Small cell undifferentiated / anaplastic pattern | 0 (0%) |
Mixed Epithelial / Mesenchymal Type | 8 (25.81%) |
Initial maximal tumor diameter, medium (IQR), cm | 9.50 (8.0–12.3) |
Alpha-fetoprotein level at diagnosis, medium (IQR), log10 ng/mL | 5.09 (4.53–5.76) |
Maximal tumor diameter after neo-adjuvant chemotherapy, medium (IQR), cm | 5 (4.0–8.2) |
Alpha-fetoprotein level after neo-adjuvant chemotherapy, medium (IQR), log10 ng/mL | 2.06 (1.45–3.08) |
Follow up duration, medium (IQR), years | 5.11 (2.97–7.16) |
Mortality, n (%) | 7 (22.58%) |
Liver transplantation, n (%) | 3 (9.68%) |
Survival with native liver, n (%) | 22 (70.97%) |
Tumor recurrence after tumor resection, n (%) | 8 (25.81%) |
PRETEXT stage, n (%) | |
PRETEXT I | 1 (3.22%) |
PRETEXT II | 13 (41.94%) |
PRETEXT III | 10 (32.26%) |
PRETEXT IV | 7 (22.58%) |